Drug Information

Drug General Information
Drug ID
D0V0KJ
Former ID
DCL001110
Drug Name
IDDBCP161883
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 3 [524219]
Company
Mitsubishi Tanabe
Target and Pathway
Target(s) Dipeptidyl peptidase IV Target Info Inhibitor [532352], [537022]
KEGG Pathway Protein digestion and absorption
NetPath Pathway IL2 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
References
Ref 524219ClinicalTrials.gov (NCT01798238) Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
Ref 532352Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013 May 6;6:187-95.
Ref 537022Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.